Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.

doi:10.1016/j.bbrc.2018.04.230

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.

Biochemical and biophysical research communications - 18 Jun 2018

Sumi Toshiyuki, Hirai Sachie, Yamaguchi Miki, Tanaka Yusuke, Tada Makoto, Niki Toshiro, Takahashi Hiroki, Sakuma Yuji

Abstract excerpt

High expression levels of survivin in KRAS-mutant lung adenocarcinomas are linked with unfavorable patient outcomes, suggesting that survivin is a promising target for tumor treatment. We found that trametinib, a MEK inhibitor, downregulates survivin expression in the RB1-positive KRAS-mutant lung adenocarcinoma cell lines H358 and H441. In these cell lines, trametinib treatment induced p21 expression and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Gene Knockdown Techniques

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Inhibitor of Apoptosis Proteins

Share to Pyridones

Share to Pyrimidinones

Share to Retinoblastoma Binding Proteins

Share to Survivin

Share to Ubiquitin-Protein Ligases

Source

Open in PubMed

Identifiers

PMID: 29727601
DOI: 10.1016/j.bbrc.2018.04.230

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.